T HE GENE ENCODING calpain-10 (CAPN10), located on chromosome 2q37, has been identified as a candidate gene for type 2 diabetes (1). In Pima Indians, the diabetes-associated intronic single-nucleotide polymorphism (SNP)-43 G/G genotype was associated with reduced muscle CAPN10 mRNA expression and impaired insulinstimulated glucose metabolism, mainly impaired glucose oxidation (2) . Calpain-10 is a cysteine protease expressed in many tissues important in glucose metabolism, including skeletal muscle, liver, pancreas, and adipose tissue (3, 4) , but the explanation for how calpain-10 increases susceptibility for type 2 diabetes is not yet completely known. Recent results suggest that calpain-10 may be involved in both glucose transporter 4 translocation to the cell membrane in adipocytes (5) as well as pancreatic ␤-cell insulin secretion (6) .
The relationship between obesity and type 2 diabetes has long been recognized, and although not all obese subjects develop type 2 diabetes, the majority of the latter patients are obese. Free fatty acid (FFA) levels are increased in obese individuals, primarily due to an increase in the rate of lipolysis from the expanded fat cell mass, and have been suggested to play an essential role in the development of skeletal muscle insulin resistance (7) (8) (9) (10) . In skeletal muscle, an increased flux of FFAs increase intramyocellular triglyceride stores, and this enhanced intracellular lipid accumulation is significantly and inversely correlated with insulin sensitivity (11, 12) . Recently, SNPs or their combinations in CAPN10 have been shown to predispose to insulin resistance and elevated FFA levels (13) . Genetic variation in CAPN10 has also been associated with both reduced ␤ 3 -adrenoeceptor function in adipocytes from obese subjects (14) and increased plasma cholesterol in Japanese (15) . Our aim was to investigate the possible role of CAPN10 in obesity and related features. In the present study, we performed a case control association study for obesity, and a transmission disequilibrium test (TDT) for offspring with abdominal obesity, and studied the expression of CAPN10 in adipose tissue and whether it is influenced by variation in the gene.
Subjects and Methods

Study subjects
The case control study consisted of 235 obese nondiabetic Swedish subjects [age, 43 Ϯ 12 yr; body mass index (BMI), 40 (35-45) kg/m 2 ] and 235 controls matched for age and gender [age, 43 Ϯ 12 yr; BMI, 22 (21) (22) (23) (24) kg/m 2 ; Table 1 ]. One hundred sixteen parents-offspring trios, where the offspring was abdominally obese (waist, Ͼ80 and Ͼ94 cm for females and males, respectively; Table 1 ), were genotyped to follow transmission of CAPN10 SNP-43 alleles. Abdominal visceral and sc adipose tissues were obtained from 33 of the obese subjects participating in the case control study when they were undergoing bariatric surgery at Landskrona Hospital in Sweden (age, 39 Ϯ 10 yr; BMI, 41 Ϯ 5 kg/m 2 ; Table  1 ). Biopsies were immediately frozen in liquid nitrogen and stored at Ϫ80 C until further processing. All subjects gave informed consent, and the study was approved by the local ethics committee.
Abbreviations: BMI, Body mass index; FFA, free fatty acid; SNP, single-nucleotide polymorphism; TDT, transmission disequilibrium test; WHR, waist-to-hip ratio.
Body weight and height were measured with subjects in light clothing without shoes, and BMI was calculated as weight (kilograms) divided by height (meters) squared. Waist circumference was measured with a soft tape on standing subjects midway between the lowest rib and the iliac crest. Hip circumference was measured over the widest part of the gluteal region, and waist-to-hip ratio (WHR) was accordingly calculated. Plasma glucose was determined using an automated glucose oxidase method (Glucose Analyzer 2; Beckman Instruments, Fullerton, CA). Serum insulin concentrations were measured with RIA (Pharmacia, Uppsala, Sweden). Triglyceride concentrations were measured on a Cobas Mira analyzer (Hoffmann-La Roche, Basel, Switzerland). Total body fat percentage was calculated using bioimpedance analysis.
Genotyping
DNA was extracted from blood using a conventional method (16) or using DNA Mini-Prep (Qiagen, Hilden, Germany) at the DNA/RNA Genotyping Lab, SWEGENE Resource Center for Profiling Polygenic Disease, Lund University, Malmö University Hospital (Malmö , Sweden). In the case control study, the CAPN10 SNP-43 was amplified with primers 5Ј-GCT GGC TGG TGA CAT CAG TGC-3Ј and 5Ј-ACC AAG TCA AGG CTT AGC CTC ACC TTC ATA-3Ј. PCR was carried out in a 20-l volume containing 10 m each dNTP, 3.0 mm MgCl 2 , 0.5 U Taq polymerase (Amersham Pharmacia Biotech, Piscataway, NJ), 10 pmol each primer, and 25 ng genomic DNA. The cycling conditions were 94 C for 5 min, 32 cycles of 94 C for 30 sec, 60 C for 30 sec, and 72 C for 30 sec, followed by a final extension at 72 C for 10 min. PCR products were digested with 10 U NdeI (New England Biolabs, Beverly, MA) for 16 h at 37 C. The digested products were separated on a 4% agarose gel. Allele G was detected as a 254-bp fragment, and allele A as 223-and 31-bp fragments. In the TDT, CAPN10 SNP-43 was genotyped using allelic discrimination in the ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) in a 5-l reaction according to the manufacturer's instructions. Primers and probes were designed using Assays-by-Design (Applied Biosystems) and were as follows: forward primer, 5Ј-GCG CTC ACG CTT GCT-3Ј; reverse primer, 5Ј-CCT CAC CAA GTC AAG GCT TAG C-3Ј; probe G, 5Ј-(VIC)-AAG TAA GGC GTT TGA AG-(nonfluorescent quencher)-3Ј; and probe A, 5Ј-(FAM)-AAG TAA GGC ATT TGA AG-(nonfluorescent quencher)-3Ј.
Measurement of CAPN10 mRNA using real-time RT-PCR
Extraction of total RNA from the fat biopsies was performed with the RNeasy mini-kit (Qiagen), and cDNA was synthesized using Superscript II RNase H Ϫ Reverse Transcriptase (Life Technologies, Rockville, MD) and random hexamer primers (Life Technologies). Real-time semiquantitative RT-PCR was performed using the ABI PRISM 7900 Sequence Detection System (Applied Biosystems) according to the manufacturer's instructions. PCR were run in 25 l containing 12.5 l Mastermix, 1.25 l primers and probe, and 75 ng cDNA. Cyclophilin A was used as an endogenous control to standardize the amount of cDNA added to the reactions using a ready-to-use mix of primers and a VIClabeled probe. Primers and probe for CAPN10 mRNA were ordered as a ready-to-use mix of primers and a FAM-labeled probe. All reagents were purchased from Applied Biosystems. The CAPN10 primers and probe recognize seven of the eight isoforms of calpain-10, which is important because it was shown that reduced skeletal muscle CAPN10 transcript levels are due to a cumulative decrease in major isoforms (17) . All samples were run in duplicate, and data were calculated using the standard curve method and expressed as a ratio to the Cyclophilin A reference.
Statistical analyses
Descriptive data displaying normal distribution are presented as means Ϯ sd, whereas data that were not normally distributed are given as median and interquartile range in parentheses. Expression data are presented as means Ϯ sem. Values of P Ͻ 0.05 were considered statistically significant. Statistical calculations were performed using NCSS 2000 software (NCSS, Kaysville, UT). CAPN10 mRNA levels in visceral and sc adipose tissue were log-transformed to get a normal distribution. Otherwise, nonparametric statistical calculations (Wilcoxon betweenand Mann-Whitney within-groups, and Spearman for correlation analysis) were used. The 2 test was used to compare allele and genotype frequencies between groups, and also to identify significant departures from the Hardy-Weinberg equilibrium. The TDT was performed using Genhunter 2.1 (18) .
Results
Case control association study
There were no significant differences in genotype (G/G, 51 vs. 52%; G/A, 41 vs. 42%; and A/A, 8 vs. 6%; P ϭ 0.7) or allele frequencies (G, 72 vs. 73%; A, 28 vs. 27%; P ϭ 0.9) between the obese subjects and the controls regarding CAPN10 SNP-43 ( Table 2 ). The genotype frequencies were in HardyWeinberg equilibrium. No significant differences were found between subjects homozygous for the SNP-43 G allele and carriers of the A allele regarding age, BMI, waist, WHR, fasting plasma glucose, or triglyceride levels in the controls (Table 3) . On the other hand, obese subjects carrying the SNP-43 G/G genotype had significantly elevated triglyceride levels compared with subjects carrying the SNP-43 G/A or A/A genotype [1.7 (1.1-2.4) vs. 1.4 (1.0 -2.0); P ϭ 0.03], but no differences regarding age, BMI, waist, WHR, or fasting plasma glucose were seen (Table 3) . Data are means Ϯ SD or median (range). Only P values of 0.05 or less are given. f, Female; m, male; N/A, not applicable; fP, fasting plasma; tg, triglycerides.
a P Ͻ 0.0001 compared to obese subjects.
TDT
Ninety-six of 232 transmissions were informative. The CAPN10 SNP-43 alleles showed no significant departure from the expected Mendelian 50:50 ratio in the TDT (49 vs. 47 transmissions of the G and A allele, respectively; P ϭ 0.84).
CAPN10 mRNA expression in visceral and sc adipose tissue
The mRNA levels of CAPN10 were increased in visceral compared with sc fat obtained from obese subjects undergoing bariatric surgery (0.58 Ϯ 0.06 vs. 0.41 Ϯ 0.04; P ϭ 0.001; Fig. 1 ). We found an inverse relationship between CAPN10 mRNA expression in sc adipose tissue and total body fat percentage (R ϭ Ϫ0.43; P ϭ 0.02; Fig. 2 ) and a trend in the same direction for visceral fat and CAPN10 mRNA expression (R ϭ Ϫ0.28; P ϭ 0.14). Visceral and sc CAPN10 mRNA levels were also correlated to each other (R ϭ 0.49; P ϭ 0.004; Fig. 3 ). The CAPN10 mRNA expression in sc fat was significantly reduced in subjects with the SNP-43 G/G genotype compared with carriers of SNP-43 G/A [G/G, 0.33 Ϯ 0.02 (n ϭ 18), vs. G/A, 0.51 Ϯ 0.09 (n ϭ 15); P ϭ 0.048], and a similar trend was observed in visceral fat [G/G, 0.52 Ϯ 0.06 (n ϭ 18), vs. G/A, 0.65 Ϯ 0.10 (n ϭ 15); P ϭ 0.22; Fig. 4 ]. None of these subjects carried the rare A/A genotype.
Discussion
The main findings of this study were that 1) CAPN10 SNP-43 showed no association to obesity in the case control association study or in the TDT, 2) variation in CAPN10 SNP-43 was associated with triglyceride levels in obese subjects, 3) the expression of CAPN10 mRNA was higher in visceral compared with sc adipose tissue, 4) there was a positive correlation between CAPN10 mRNA levels in the two different fat depots, and 5) variation in CAPN10 SNP-43 was associated with the expression of CAPN10 mRNA at least in sc fat.
Our finding that obese subjects carrying the SNP-43 G/G genotype have significantly higher triglyceride levels than subjects with the A allele are in agreement with earlier findings showing that fasting FFA levels are significantly higher in carriers of the SNP-43 G allele compared with carriers of the A/A genotype (13) . Interestingly, this was not the case among our controls, suggesting that the effect of the genotype is manifested only under certain conditions, i.e. obesity. It can also be a reflection of the lack of power. There was no association between variants in CAPN10 SNP-43 and obesity in the case control association study or in the TDT performed with abdominal obese offspring, suggesting that calpain-10, or at least the CAPN10 SNP-43, is involved in the development of insulin resistance rather than in the development of obesity per se. Many studies investigating the role of CAPN10 in type 2 diabetes, have evaluated its influence on BMI, WHR, and/or total body fat mass. Most of the studies failed to show any significant associations between variation in CAPN10 and obesity-related parameters (2, 13, 19 -27) . In addition, an analysis of the relationship between variation in CAPN10 and extreme early-onset obesity revealed no evidence for linkage or association (28) . One smaller case control study for CAPN10 and obesity has been performed earlier in a Scandinavian population, and it failed to show association to SNP-19, -43, and -63 (14) . However, a TDT performed with obese, type 2 diabetic offspring showed increased transmission of the less common C allele at SNP-44 to affected probands (29) . Contrary to what might be expected, a quantitative TDT in South Indians found that transmission of the SNP-43 G allele or the type 2 diabetes-risk haplotype 1121 (SNP-44, -43, -19, and -63) to the diabetic offspring was associated with a decrease in BMI and hip size (30) . In a study of healthy nonobese subjects, individuals with the CAPN10 SNP-43 G/G genotype had significantly lower BMI compared with carriers of the A allele (31) . Recently published results showed that the CAPN10 SNP-19 and -63 are associated with BMI in Japanese (32) .
SNP-43 is located in intron 3 of CAPN10, and this polymorphism has been suggested as a regulator of CAPN10 expression (1) . In Pima Indians with normal glucose tolerance, carriers of the CAPN10 SNP-43 G/G genotype showed lower expression levels of CAPN10 mRNA compared with carriers of the A allele in skeletal muscle (2) . We observed the same in adipose tissue from obese Swedish subjects, although it reached statistical significance only in sc adipose tissue. This is in accordance with the common variant hypothesis suggesting that variants that increase susceptibility for a complex polygenic disease do so through effects on gene expression (33) . In addition, we found that the expression of CAPN10 in sc adipose tissue is inversely correlated to total body fat percentage, suggesting that a larger proportion of body fat in the already-obese subjects, corresponding to a reduced CAPN10 expression, is associated with an increased risk of metabolic perturbation. However, it should be pointed out that the expression levels of CAPN10 were studied in a very obese population. CAPN10 mRNA was more abundant in visceral than in sc fat, which is interesting because visceral fat is more metabolically active than sc (34) . On the other hand, CAPN10 mRNA levels in sc and visceral adipose tissue were positively correlated to each other suggesting that the expression of CAPN10 is coregulated in the two different adipose depots.
In conclusion, intronic variation in CAPN10 is associated with elevated triglyceride levels and reduced adipose tissue mRNA expression in morbidly obese Swedish subjects, suggesting that a low CAPN10 expression may be a risk factor for conditions related to the metabolic syndrome. 
